Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Tegafur Gimeracil Oteracil is named as an intervention in 37 current clinical trials in our China, USA, UK and India registers. 19 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Ruijin Hospital (4). The most-studied condition is Gastric Cancer.

Trials by status

Recruiting1951%
Not yet open1027%
Active, closed719%
By invitation13%

Trials by phase

Phase 22259%
Phase 3719%
Phase 1/238%
Phase 2/325%
Phase 413%
Phase EARLY_PHASE113%
Observational13%

Clinical trials of Tegafur Gimeracil Oteracil

37 trials

Study	Phase	Status	Lead sponsor	Registers
Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 NCT05593458 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Carcinoma	Phase 3	Recruiting	Zhejiang University	China
Study of Comparing of With and Without Sequential Therapy of S-1 NCT05813015 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect	Phase 3	Recruiting	Zhejiang University	China
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer NCT06194734 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Beijing Konruns Pharmaceutical Co., Ltd.	China
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer NCT07366528 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer	Phase 3	Recruiting	Ruijin Hospital	China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer NCT05699655 · ClinicalTrials.gov ↗ · Immunotherapy Gastrict Cancer	Phase 2/3	Recruiting	Fujian Cancer Hospital	China
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma NCT04989985 · ClinicalTrials.gov ↗ · Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) NCT06187597 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM NCT06341595 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer NCT06451211 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach	Phase 2	Recruiting	Sun Yat-sen University	China
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer NCT06555471 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma NCT06664021 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Anhui Provincial Hospital	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer NCT07194005 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Fudan University	China
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis NCT07384234 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2 NCT05403242 · ClinicalTrials.gov ↗ · Advanced Gastroesophageal Adenocarcinoma	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 1/2	Recruiting	Ruijin Hospital	China
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study NCT07640048 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis NCT06779318 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy	Phase 4	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer NCT06255379 · ClinicalTrials.gov ↗ · Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer	Phase 2	Not yet open	Guangzhou University of Traditional Chinese Medicine	China
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer NCT06454435 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer NCT07018063 · ClinicalTrials.gov ↗ · Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced	Phase 2	Not yet open	zhoujing	China
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma NCT07374250 · ClinicalTrials.gov ↗ · Gastric Cancer, RCT	Phase 2	Not yet open	Sichuan University	China
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study NCT07685704 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer	Phase 2	Not yet open	Zhifeng Zhao, PhD	China
Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT07733050 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	Shanghai General Hospital, China	China
Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer NCT07745790 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms	Phase 2	Not yet open	Ruijin Hospital	China
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma NCT07828873 · ClinicalTrials.gov ↗ · Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07356466 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer	Phase EARLY_PHASE1	By invitation	Fujian Medical University	China
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT05144854 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Active, closed	Ono Pharmaceutical Co., Ltd.	China
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) NCT06109779 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT06256328 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Ono Pharmaceutical Co., Ltd.	China
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC NCT06490107 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression NCT06939452 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction NCT07776639 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Tegafur Gimeracil Oteracil

49 conditions

Gastric Cancer11 Biliary Tract Cancer4 Gastroesophageal Junction Adenocarcinoma3 Pancreatic Cancer2 Gastric Adenocarcinoma2 HER2-positive Gastric Cancer2 Chemotherapy Effect2Locally Advanced Gastric Carcinoma1Gastroesophageal-junction Cancer1Postoperative Adjuvant Therapy1Maintenance Therapy1Locally Advanced Esophageal Squamous Cell Carcinoma1

All 49 conditions

Condition (as registered)	Trials
Gastric Cancer	11
Biliary Tract Cancer	4
Gastroesophageal Junction Adenocarcinoma	3
Pancreatic Cancer	2
Gastric Adenocarcinoma	2
HER2-positive Gastric Cancer	2
Chemotherapy Effect	2
Locally Advanced Gastric Carcinoma	1
Gastroesophageal-junction Cancer	1
Postoperative Adjuvant Therapy	1
Maintenance Therapy	1
Locally Advanced Esophageal Squamous Cell Carcinoma	1
Gastric (Cardia, Body) Cancer	1
Stomach Adenocarcinoma	1
Locally Advanced	1
Gastric (Stomach) Cancer	1
RCT	1
Gastric Cancer Metastatic to Regional Lymph Nodes	1
Immunotherapy Gastrict Cancer	1
Esophageal Squamous Cell Carcinoma	1
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	1
Pancreatic Ductal Adenocarcinoma	1
Liver Neoplasms	1
Lung Neoplasms	1
Metastatic Pancreatic Ductal Adenocarcinoma	1
Intrahepatic Cholangiocarcinoma	1
PDAC - Pancreatic Ductal Adenocarcinoma	1
Pancreas Cancer	1
Pancreatic Neoplasms	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Gastric Cancer (GC)	1
Adjuvant Chemotherapy	1
Stage 3 Cancer	1
Docetaxel	1
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Locally Advanced Gastroesophageal Junction Adenocarcinoma	1
Second Line Treatment	1
Chemotherapy	1
Tyrosine Kinase Inhibitor	1
Stomach Neoplasms	1
Linitis Plastica of Stomach	1
Metastasis Colorectal Cancer	1
Colon Cancer	1
Rectal Cancer	1
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
Locally Advanced Gastric Adenocarcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	36	19
Clinical trials in USA	2	0
Clinical trials in UK	1	0
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Tegafur Gimeracil Oteracil trials

How many clinical trials are testing Tegafur Gimeracil Oteracil?

37 current trials in our China, USA, UK and India registers name Tegafur Gimeracil Oteracil (also registered as S-1) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Tegafur Gimeracil Oteracil trials recruiting patients?

Yes. 19 of the 37 trials are recruiting: 19 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tegafur Gimeracil Oteracil clinical trials?

Ruijin Hospital (4), The First Affiliated Hospital with Nanjing Medical University (3), Sun Yat-sen University (3) and AstraZeneca (2), among 25 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tegafur Gimeracil Oteracil works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tegafur Gimeracil Oteracil works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tegafur Gimeracil Oteracil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tegafur Gimeracil Oteracil clinical trials